IP Library Granted Patent US 10,376,578
Granted Patent B2
US 10,376,578 · App. 15/483,702 · Granted Aug 13, 2019

Compositions and methods for treating Crohn's disease and related conditions and infections

Inventor: Gaurav Agrawal (Manly, AU)
Assignee: Guarav Agrawal
A61K39/39533A23C9/123A23G3/36A23G4/06A23G9/32A61K31/133A61K31/4164A61K31/435A61K31/496A61K31/498A61K31/7048A61K33/00A61K39/3955A61K39/40A61K2039/505Y02A50/474
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,376,578
App. No.
15/483,702
Granted
Aug 13, 2019
Kind
B2
Abstract

In alternative embodiments, the invention provides a “triple combination” therapy for treating, ameliorating and preventing Crohn's Disease (or Crohn syndrome, terminal or distal ileitis or regional enteritis) or related disorders and conditions in mammals, such as paratuberculosis in mammals, or Johne's disease, including genetically-predisposed and chronic disorders, where the microbial or bacterial flora of the bowel is at least one causative or symptom-producing factor; and compositions for practicing same. In alternative embodiments, methods and compositions of the invention comprise or comprise use of therapies, medications, formulations and pharmaceuticals comprising active agents that can suppress or eradicate the microbiota super-infection that causes Crohn's Disease or paratuberculosis infection in mammals. In alternative embodiments, the methods and uses of the invention for treating, ameliorating and preventing Crohn's Disease and complications of Crohn's Disease, or related disorders and conditions in mammals, such as paratuberculosis in mammals, or Johne's disease, comprises administration to an individual (human or mammal) in need thereof: (1) an anti-TNFα composition, or a composition capable of down-modulating TNFα activity; (2) a Hyperbaric Oxygen Treatment, or HBOT; and (3) an anti- Mycobacterium avium sub species paratuberculosis (MAP) (an anti-MAP) agent, composition or therapy.

Claims (12)

1. A therapeutic combination for treating or ameliorating:

a Crohn's Disease, or

a complication of a Crohn's Disease,

comprising:

(1) an anti-TNFα agent, composition or drug, or an agent, a composition or a drug capable of down-modulating or down-regulating a TNFα activity;

(2) an anti- Mycobacterium avium sub species paratuberculosis (MAP) (an anti-MAP) agent, composition, or drug; and

(3) hyperbaric oxygen.

2. The a therapeutic combination of claim 1 , wherein

the anti-TNFα agent, composition or drug, or the agent, composition or drug capable of down-modulating or down-regulating a TNFα activity, comprises: infliximab; adalimumab; certolizumab, golimumab; basiliximab; daclizumab; omalizumab; or, any combination thereof.

3. The therapeutic combination of claim 1 , wherein the anti-MAP agent, composition, or drug comprises rifabutin or clarithromycin.

4. The therapeutic combination of claim 1 , comprising a combination of rifabutin and clarithromycin.

5. The therapeutic combination of claim 1 , wherein the Crohn's Disease is a fistulising Crohn's Disease, or a complication of a fistulising Crohn's Disease, or a Crohn's Disease-related fistulae.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 5, 2024
From: GAURAV AGRAWAL
To: CENTRE FOR DIGESTIVE DISEASES
Reel/Frame 066385/0322 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 18, 2018
From: CENTRE FOR DIGESTIVE DISEASES
To: AGRAWAL, GUARAV
Reel/Frame 047270/0316 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 12, 2018
From: CENTRE FOR DIGESTIVE DISEASES
To: AGRAWAL, GUARAV
Reel/Frame 047573/0316 →
Priority Claims (1)
AU 2012902307 · Jun 4, 2012 · national
Continuity (2)
Continuation 14405384
Related Publication 20170274071A1 · Sep 28, 2017